Champions Oncology Posts Record $59.4M Annual Revenue and Fourth Consecutive Quarter of Positive Adjusted EBITDA
CSBR is trading near its 52-week low of $5.5 (14% above the low).
Summary
Champions Oncology delivered record fiscal 2026 revenue of $59.4 million and its fourth consecutive quarter of positive Adjusted EBITDA. The core business is strengthening, but strategic investments resulted in a GAAP net loss.
Key Events · Earnings and Guidance · CSBR
-
Record Annual Revenue
Fiscal 2026 revenue climbed 4% to a record $59.4 million, as growth in core research services more than offset the absence of a $4.5 million data licensing deal that was recognized in fiscal 2025.
-
Fourth Consecutive Quarter of Positive Adjusted EBITDA
Adjusted EBITDA reached $158,000 for the fourth quarter and $1.6 million for the full year, marking four straight quarters in positive territory and highlighting improved operating leverage.
-
Strategic Investments Pressure GAAP Profitability
A GAAP net loss of $1.2 million for fiscal 2026—compared with net income of $4.7 million in the prior year—reflects deliberate spending on radiopharmaceutical capabilities, the data platform, and commercial expansion.
-
Cash Position and Operating Cash Burn
The company ended the year with $4.9 million in cash and no debt, though net cash used in operating activities totaled $4.5 million, driven largely by working capital timing and growth investments.
Analysis · CSBR · Life Sciences
A record $59.4 million in annual revenue—up 4% year-over-year—and a fourth straight quarter of positive Adjusted EBITDA underscore Champions Oncology's strengthening core. Growth in research services more than compensated for the absence of a prior-year data licensing deal. Strategic investments in radiopharmaceuticals, the data platform, and commercial expansion pushed the company to a GAAP net loss of $1.2 million, yet underlying operational trends continue to improve. With $4.9 million in cash and no debt, the balance sheet is clean, though the $4.5 million in operating cash burn for the year merits close attention. For a small-cap life sciences firm, the results signal disciplined investment for growth alongside careful cost management.
At the time of this filing, CSBR was trading at $6.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.2M. The 52-week trading range was $5.50 to $8.74. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.